Skip to main content
. 2019 Jun 6;7(11):1270–1281. doi: 10.12998/wjcc.v7.i11.1270

Table 2.

Outcomes between treated, untreated, and uninfected cohorts, n = 6266

Treated cohort (n = 482) Untreated cohort (n = 1928) Uninfected cohort (n = 3856) P value
End-stage renal disease
Events number (%) 5 (1.0) 134 (7.0) 188 (4.9) < 0.0001
Competing mortality (%) 58 (12.0) 573 (29.7) 775 (20.1) < 0.0001
Cumulative incidence (%) 2.4 (95%CI: 0.9-5.2) 11.7 (95%CI: 8.0-16.1) 8.2 (95%CI: 6.2-10.5) 0.0032
Overall mortality
Events number (%) 61 (12.7) 648 (33.6) 861 (22.3) < 0.0001
Cumulative incidence (%) 41.4 (95%CI: 8.1-54.1) 58.0 (95%CI: 51.5-63.9) 37.8 (95%CI: 34.4-41.3) < 0.0001